Enola, eres la savia que alimenta el hilo. Sigo más atento que nunca y con mucha moral con THLD, lástima del descalabro que llevó hoy mi cartera, especialmente en bancos. Es que voy de "largoplacista resignado" en BBVA a 11,88 y un poco mejor con Caixabank (que las tuve en máximos y no quise vender.... en fin...)
Cordial saludo a todos tus fans
Hola Patatu, yo mismo también he dudado al leer el post de Enola. Dentro de las operaciones que llevo hechas en el año que llevo en bolsa, no me había planteado aún vender solo una parte. Si el beneficio lo creo bueno, me salgo con todo. Quizá sea porque hago compras de cantidades pequeñas de no más de 4.000€. Así que parece que cunda poco si te dejas la mitad. Aunque tampoco suelo comprar valores digamos de... compleja cotización.
"I am excited to join the Threshold team and have the opportunity tohelp bring a truly innovative therapy to market. TH-302 has thepotential to significantly benefit cancer patients and I'm lookingforward to playing a role in supporting the development of thispromising drug candidate," said Dr. Pearce
Threshold Pharmaceuticals Appoints Dr. Tillman Pearce as Chief2012-02-17 10:15:00.63 GMT Threshold Pharmaceuticals Appoints Dr. Tillman Pearce as ChiefMedical Officer SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 02/17/12
-- ThresholdPharmaceuticals, Inc. (NASDAQ: THLD) today announced the appointmentof Tillman Pearce, M.D. as its Chief Medical Officer. In thisposition, Dr. Pearce will oversee the development of Threshold'sTH-302, a clinical stage hypoxia-targeted cancer therapeuticcurrently being evaluated in a variety of cancers, including a Phase3 trial in patients with soft tissue sarcoma and a Phase 2b trial inpatients with pancreatic cancer. "Dr. Pearce's experience in oncology drug development, from theperspectives of large pharmaceutical as well as smallerentrepreneurial biotech companies, will be a significant addition toThreshold," stated Barry Selick, Ph.D., Chief Executive Officer ofThreshold.
"We enthusiastically welcome Tillman to the team and lookforward to his contributions as we advance the development of TH-302while building our new partnership with Merck KGaA. At this time, wealso want to acknowledge and thank Dr. Sam Saks who joined us asinterim CMO immediately following Dr. John Curd's sudden passing lastSpring. Sam's insight into oncology drug development in general andTH-302 in particular has been invaluable to us and he will continueto be a key advisor to Threshold."
Dr. Pearce brings almost two decades of international experience indrug development, including the pre- and post-marketing developmentof a variety of novel therapeutics for the treatment of solid tumorsand hematologic malignancies as well as for inflammatory andinfectious diseases.
He served in senior managerial posts includingDirector of Oncology Clinical Research for Sandoz/Novartis where heworked on Phase 1-3 studies of PSC833 in hematologic malignancies andsolid tumor indications, Medical Director at Sanofi-Synthelabo'sOncology Business Unit during the international launch of Eloxatinfor the treatment of colorectal cancer, and he established anddirected PDL BioPharma France, which was responsible for PDL'sclinical activities throughout Europe.
Most recently, Dr. Pearceserved as Chief Medical Officer of KaloBios Pharmaceuticals. "I am excited to join the Threshold team and have the opportunity tohelp bring a truly innovative therapy to market. TH-302 has thepotential to significantly benefit cancer patients and I'm lookingforward to playing a role in supporting the development of thispromising drug candidate," said Dr. Pearce. Dr. Pearce has a Bachelor's degree in philosophy from TulaneUniversity, New Orleans, LA, and a medical degree from the MedicalCollege of Georgia, Augusta, GA. Dr. Pearce is a board certifiedinternist and hematologist.